In gliomas, both SphK1 and SphK2 were abnormally upregulated in tumor tissues and cell lines, and a higher expression of SphKs means lower survival times of glioma patients (Li et al., 2008; Liu et al., 2018). This evidence concerns the gene SPHK1 and central nervous system cancer.